Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) rose 9.8% during mid-day trading on Monday . The stock traded as high as $6.20 and last traded at $6.07. Approximately 1,253,302 shares were traded during trading, an increase of 31% from the average daily volume of 955,419 shares. The stock had previously closed at $5.53.

APTO has been the topic of several analyst reports. Piper Sandler restated an “overweight” rating and set a $10.00 price objective on shares of Aptose Biosciences in a report on Tuesday, June 23rd. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Aptose Biosciences in a report on Friday, June 12th. Zacks Investment Research lowered Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 7th. Maxim Group started coverage on Aptose Biosciences in a research report on Friday, June 12th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Oppenheimer started coverage on Aptose Biosciences in a research report on Sunday, June 14th. They issued a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Aptose Biosciences presently has a consensus rating of “Buy” and an average target price of $10.79.

The stock has a 50-day simple moving average of $5.27 and a 200-day simple moving average of $6.40. The company has a market cap of $539.26 million, a price-to-earnings ratio of -9.87 and a beta of 1.69.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.06). Equities analysts forecast that Aptose Biosciences Inc. will post -0.77 earnings per share for the current fiscal year.

In other news, VP Jotin Marango sold 62,835 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.05, for a total value of $380,151.75. Following the sale, the vice president now owns 116,219 shares of the company’s stock, valued at approximately $703,124.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Warren Whitehead sold 18,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $7.11, for a total value of $127,980.00. Following the completion of the sale, the director now directly owns 51,250 shares in the company, valued at approximately $364,387.50. The disclosure for this sale can be found here. Insiders have sold a total of 397,340 shares of company stock valued at $2,429,061 in the last quarter. 6.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of APTO. Corriente Advisors LLC raised its stake in shares of Aptose Biosciences by 544.1% in the 1st quarter. Corriente Advisors LLC now owns 2,918,000 shares of the biotechnology company’s stock worth $17,333,000 after buying an additional 2,464,960 shares in the last quarter. Pictet Asset Management Ltd. bought a new stake in shares of Aptose Biosciences in the 1st quarter worth $9,158,000. Prosight Management LP bought a new stake in shares of Aptose Biosciences in the 2nd quarter worth $4,941,000. Logos Global Management LP bought a new stake in shares of Aptose Biosciences in the 2nd quarter worth $4,733,000. Finally, Precept Management LLC raised its stake in shares of Aptose Biosciences by 72.5% in the 1st quarter. Precept Management LLC now owns 776,196 shares of the biotechnology company’s stock worth $4,611,000 after buying an additional 326,196 shares in the last quarter. 40.30% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile (NASDAQ:APTO)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: What are momentum indicators and what do they show?

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.